Gore Partners with Medinol on the Rebound in Global Stent Deal

WL Gore & Associates and Tel Aviv, Israel-based Medinol, both privately-held companies, enetered into a worldwide partnership agreement covering stents and stent systems, the exact terms of which have not been disclosed. What's clear, however, is that the deal enables each company to fill a significant hole in their interventional cardiology product lines, while also restoring worldwide distribution channels for Medinol. The Israeli company, which focuses exclusively on developing and manufacturing innovative stent technology, lost its sales and marketing channel this year after dissolving a longstanding agreement with Boston Scientific. Now, it will be able to utilize the balloon and stent delivery system that Gore plans on unveiling later this year, along with Gore's distribution network, while Gore will have access to Medinol's ionnovative stent line, including the new NIRflex stent.

As the stent market matures, how much value exists in having a balloon and a delivery system but not a stent? And similarly, how valuable is innovative stent technology without significant distribution capability? In both cases, the answer is apparently not enough in the views of W.L Gore & Associates Inc. and Tel Aviv, Israel-based Medinol Ltd. The two privately -held companies entered into a worldwide partnership agreement covering stents and stent systems, the exact terms of which have not been disclosed. [See Deal]. What's clear, however, is that the deal enables each company to fill a significant hole in their interventional cardiology product lines, while also restoring worldwide distribution channels for Medinol. The Israeli company, which focuses exclusively on developing and manufacturing innovative stent technology, lost its sales and marketing channel this year after dissolving a longstanding agreement with Boston Scientific Corp. Now, it will be able to utilize the balloon and stent delivery system that Gore plans on unveiling later this year, along with Gore's distribution network, while Gore will have access to Medinol's innovative stent line, including the new NIRflex stent.

Medinol had been Boston Scientific's exclusive stent supplier since the two companies signed a ten-year worldwide distribution agreement in 1995....

Welcome to In Vivo

Create an account to read this article

More from Innovation

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By 

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

More from In Vivo

When VC Steps Back: Finding Alternative Biotech Funding

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By 

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.